Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: IndiaNivesh Securities Pvt Ltd
$115.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cadila Healthcare Ltd Receives Tentative Approval For Amlodipine Besylate And Benazepril Hydrochloride Capsules


Sunday, 31 Mar 2013 10:45pm EDT 

Cadila Healthcare Ltd announced that it has received tentative approval from the USFDA for Amlodipine Besylate and Benazepril hydrochloride capsules. It falls in the anti-hypertensive segment.